Linagliptin

Izina ryimiti:

8 - [(3R) -3-aminopiperidin-1-yl] -7- (ariko-2-yn-1-yl) -3- methyl-1 - , 7-dihydro-1H-purine-2,6-dione

Kode ya SMILES:

O = C (N1CC2 = NC (C) = C3C = CC = CC3 = N2) N (C) C4 = C (N (CC # CC) C (N5C [C @ H] (N) CCC5) = N4) C1 = O.

InChi Code:

InChI = 1S / C25H28N8O2 / c1-4-5-13-32-21-22 (29-24 (32) 31-12-8-9-17 (26) 14-31) 30 (3) 25 (35) 33 (23 (21) 34) 15-20-27-16 (2) 18-10-6-7-11-19 (18) 28-20 / h6-7,10-11,17H, 8-9, 12-15,26H2,1-3H3 / t17- / m1 / s1

InChi Urufunguzo:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Ijambo ryibanze:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Gukemura:Gukemura muri DMSO

Ububiko:0 - 4 ° C mugihe gito (iminsi kugeza ibyumweru), cyangwa -20 ° C mugihe kirekire (amezi).

Ibisobanuro:

Linagliptin, izwi kandi ku izina rya BI-1356, ni inhibitor ya DPP-4 yakozwe na Boehringer Ingelheim mu kuvura diyabete yo mu bwoko bwa II. Linagliptin (rimwe ku munsi) yemejwe na FDA yo muri Amerika ku ya 2 Gicurasi 2011 kugira ngo ivure diyabete yo mu bwoko bwa II. Irimo kugurishwa na Boehringer Ingelheim na Lilly.

Intego: DPP-4